Advertisement

Topics

FDA accepts resubmission of AZ’ potassium-binder

06:13 EDT 19 Oct 2016 | PharmaTimes

US regulators have accepted AstraZeneca unit ZS Pharma's resubmission of ZS-9, a potassium-binding compound being developed for hyperkalaemia.

Original Article: FDA accepts resubmission of AZ’ potassium-binder

NEXT ARTICLE

More From BioPortfolio on "FDA accepts resubmission of AZ’ potassium-binder"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...